- Details
- Rashid Sayyid and Zach Klaassen delve into the significance of racial disparities in prostate cancer treatment through a subgroup analysis of the ARASENS trial, which notably focused on Black patients. This pivotal trial assessed the efficacy of adding darolutamide to ADT and docetaxel in metastatic hormone-sensitive prostate cancer, revealing that Black patients, despite historically higher morta...
|
- Details
- Alicia Morgans presents a meta-analysis, undertaken with colleagues, analyzing 14 phase three trials on treatment intensification in metastatic hormone-sensitive prostate cancer. The study scrutinizes outcomes between older and younger patients, revealing that older patients exhibit a slightly diminished benefit from intensified treatments compared to their younger counterparts. Despite this, the...
|
- Details
- Michael Williams and Mark Fleming discuss their collaborative approach in managing patients with metastatic prostate cancer. Drs. Williams and Fleming emphasize the importance of multidisciplinary care, sharing a case of a patient with high-volume disease treated with an oral LHRH antagonist and enzalutamide. They highlight the need for open communication and decision-making between specialties to...
|
- Details
- Arun Azad discusses the LIBERTAS trial focusing on metastatic hormone-sensitive prostate cancer treatment with ADT plus apalutamide. The trial, aimed at improving patient outcomes and quality of life, explores the efficacy of deescalating therapy for patients achieving a PSA of less than 0.2 nanograms per milliliter after six months. The study includes a diverse patient population, irrespective of...
|
- Details
- Zach Klaassen and Peter Goebell discuss a systematic review focused on treatment intensification for metastatic hormone-sensitive prostate cancer. Dr. Goebell's study aims to assess if scientific evidence, as outlined in guidelines, translates into real-world practice changes. The review, incorporating data from 344,000 patients globally, examines the application of doublets and triplets in treatm...
|
- Details
- Benjamin Lowentritt discusses metastatic hormone-sensitive prostate cancer (mHSPC) patients' responses to ADT combined with enzalutamide or apalutamide. Dr. Lowentritt explains the study's methodology, emphasizing the importance of a deep and quick PSA response as a positive outcome marker. Initial findings suggest a faster and more prevalent PSA90 response in patients treated with apalutamide com...
|
- Details
- Zach Klaassen converses with Daniel Saltzstein about the collaborative approach to treating metastatic hormone-sensitive prostate cancer with triplet therapy or maximum androgen blockade. Dr. Saltzstein describes their unique practice set up in San Antonio, where a medical oncologist is part of their urology team. This shared patient focus facilitates seamless collaboration and treatment managemen...
|
- Details
- Zach Klaassen is joined by Chandler Park and Ryan Malone to explore the collaborative approach between GU medical oncology and urology in managing metastatic hormone-sensitive prostate cancer with triplet therapy. Drs. Park and Malone, who met through shared patients and conferences, emphasize the importance of co-management in treating these complex cases. They discuss patient selection for tripl...
|
- Details
- Zach Klaassen engages with Vahan Kassabian and Sreekanth to discuss the continuum of care for patients with metastatic hormone-sensitive prostate cancer, particularly in the context of triplet therapy based on the ARASENS data. The conversation reveals their longstanding professional relationship, developed through mutual patients and a shared interest in urological oncology. They discuss the logi...
|
- Details
- Alicia Morgans hosts a multidisciplinary discussion with David Morris and Benjamin Garmezy focusing on the treatment of newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Morris highlights the increasing trend of referring patients with high-volume Gleason 8 disease and metastatic cancer to tertiary care centers. He emphasizes the importance of early discussions about intens...
|
